300+ investors in your industry, stage, and region Get
Any industry
Community
Proptech
Biotech
Climate
Artificial Intelligence
Media (Entertainment)
Impact
FinTech
Marketplace
EdTech
Consumer
Agriculture (AgTech)
Web3
Clean Energy
B2B
Organic Food
Big Data
Video Games
Payments
Celebrity
Franchise
Mobile
Local
Social Network
Platforms
Crowdfunding
CleanTech
Film
Theatre
Life Science
Non Profit
Transportation
Gaming
Energy
Hardware
Health Care
Enterprise
Sustainability
Venture Capital
Restaurants
Fashion
Real Estate
Retail
Infrastructure
Mobile Apps
Beauty
LGBT
Publishing
Sporting Goods
Oil and Gas
Education
Renewable Energy
Food and Beverage
Cryptocurrency
Finance
Financial Services
Photography
Art
Medical
Digital Media
Music
Internet
Social Media
Manufacturing
Facebook
Blockchain
Legal
Android
Social Impact
Google
Construction
Sports
eSports
Enterprise Software
Email
Wellness
Hospitality
Travel
Fitness
Mobile Advertising
Cannabis
Recruiting
Biotechnology
Medical Device
Wine and Spirits
Automotive
Social
InsurTech
SaaS
Software
Any country
Qatar
South Korea
Africa
Asia
LATAM
Europe
Oceania
Middle East
Ireland
Singapore
Indonesia
Spain
Saudi Arabia
Belarus
Belgium
Colombia
Denmark
Ecuador
Czech Republic
Estonia
Ghana
Ethiopia
Finland
Barbados
Italy
Jersey
Cayman Islands
Mali
Malaysia
Mauritius
Poland
Rwanda
Togo
Slovenia
San Marino
Tanzania
Thailand
Uruguay
Venezuela
Portugal
Azerbaijan
Namibia
Bolivia
Latvia
Cyprus
New Zealand
United States
Germany
Australia
India
United Kingdom
Canada
China
South Africa
Brazil
Japan
Sri Lanka
Vietnam
Argentina
Armenia
Austria
Bangladesh
Bahrain
Bulgaria
Bermuda
Chile
Cameroon
Switzerland
Belize
Costa Rica
Algeria
Georgia
Egypt
Hong Kong
Gibraltar
Faroe Islands
Greece
Croatia
France
Hungary
Kuwait
Israel
Lebanon
Cambodia
Kenya
Jordan
Lithuania
Liberia
Liechtenstein
Myanmar
Kazakhstan
Morocco
Norway
Mexico
Panama
Malta
Peru
Philippines
Nicaragua
Pakistan
Russian Federation
Romania
Sweden
Serbia
Seychelles
Turkey
Puerto Rico
Sierra Leone
Senegal
Tunisia
Tajikistan
El Salvador
Uganda
Zambia
Uzbekistan
Taiwan
Ukraine
Zimbabwe
Bahamas
Guatemala
Iraq
Iceland
Nigeria
United Arab Emirates
Honduras
Isle of Man
Luxembourg
Oman
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotechnology Startup Investors in Germany (May 2026)

The most active venture capital funds and angel investors investing in Germany Biotechnology startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Germany Biotechnology startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
High-Tech Grunderfonds
VC Fund
34 Germany, Switzerland, United States Seed, Series A Software, Information Technology, Biotechnology $665k–$16M
Boehringer Ingelheim Venture Fund
VC Fund
16 United States, Germany, Belgium Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $1.3M–$50M
KfW
VC Fund
15 Germany, India, Kenya Series A, Series B Biotechnology, Software, Health Care $1.6M–$17M
NRW.BANK
VC Fund
15 Germany, United States Seed, Series A, Series B Biotechnology, Software, Health Care $107k–$13M
MIG Capital
VC Fund
15 Germany, Austria, Canada Series A, Series B Biotechnology, Health Care, Pharmaceutical $1.6M–$26M
Bayern Kapital
VC Fund
9 Germany, United States, Finland Seed, Series A Software, Information Technology, Health Care $750k–$16M
TGFS - Technologiegründerfonds Sachsen
VC Fund
8 Germany, United States Seed, Series A Software, Information Technology, Manufacturing $563k–$4.3M
Wellington Partners
VC Fund
8 Germany, United States, United Kingdom Series A, Series B Health Care, Biotechnology, Medical $3M–$43M
IFB Innovationsstarter
VC Fund
7 Germany, United States Seed, Grant Software, SaaS, Artificial Intelligence $80k–$3M
eCAPITAL ENTREPRENEURIAL PARTNERS
VC Fund
6 Germany, United States, Italy Series A, Series B Information Technology, Software, Manufacturing $1.1M–$16M
coparion
VC Fund
6 Germany, Switzerland, United States Series A, Seed, Series B Software, SaaS, FinTech $2M–$54M
BioMedPartners
VC Fund
6 Switzerland, Germany, France Series A, Series B, Series C Biotechnology, Health Care, Medical $4.4M–$69M
bmp Ventures
VC Fund
5 Germany, United States, Austria Seed, Series A Information Technology, Software, Manufacturing $29k–$4.3M
EMBL Ventures
VC Fund
5 Germany, Austria, Ireland Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $3.9M–$70M
Forbion Capital Partners
VC Fund
5 United States, United Kingdom, The Netherlands Series B, Series A, Series C Biotechnology, Health Care, Medical $4.5M–$115M
Techno Venture Management
VC Fund
5 United States, Germany, United Kingdom Series B, Series A, Series C Biotechnology, Health Care, Medical $4M–$43M
Creathor Ventures
VC Fund
5 Germany, Switzerland, United States Series A, Series B Software, Health Care, Biotechnology $2M–$16M
bm-t beteiligungsmanagement thuringen
VC Fund
5 Germany, United States Seed, Series A Software, Information Technology, Health Care $450k–$7M
Brandenburg Kapital
VC Fund
4 Germany, United Kingdom Seed, Series A Software, Information Technology, Health Care $696k–$7.4M
Amino Collective
VC Fund
4 Germany, United States, United Kingdom Seed, Series A, Pre-Seed Health Care, Biotechnology, Software $2.9M–$6M
Seed Fonds Aachen
VC Fund
4 Germany Seed, Series A Biotechnology, Medical, Health Care $2.1M–$6M
BayBG Venture Capital
VC Fund
4 Germany, Italy, United States Series A, Series B Software, Information Technology, Health Care $428k–$5.9M
S-Venture Capital Dortmund
VC Fund
4 Germany Series B, Series A Biotechnology, Guides, Genetics $3.5M–$9M
EIC Fund
VC Fund
3 Germany Seed
TVM Capital
VC Fund
3 United States, Germany, United Kingdom Series B, Series C Biotechnology, Health Care, Pharmaceutical $7.5M–$54M
CPT Capital
VC Fund
3 United States, Israel, United Kingdom Series A, Seed, Series B Food and Beverage, Food Processing, Biotechnology $1.2M–$226M
Grazia Equity
VC Fund
3 Germany, United States, Switzerland Series A, Seed, Series B Internet, E-Commerce, Biotechnology $964k–$15M
OCCIDENT
VC Fund
3 Germany, Switzerland Series A, Series C Health Care, Medical Device, Biotechnology $2.1M–$24M
Gilde Healthcare
VC Fund
3 United States, The Netherlands, Germany Series C, Series B, Series A Biotechnology, Health Care, Medical $8M–$60M
EQT life science
VC Fund
3 United States, The Netherlands, Switzerland Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $5.4M–$70M
Think.Health
VC Fund
3 Germany, United States, Switzerland Seed, Series A, Series B Health Care, Biotechnology, Medical Device $1.1M–$19M
UVC Partners
VC Fund
3 Germany, Switzerland, Denmark Seed, Series A, Series B Software, Information Technology, Artificial Intelligence $2.5M–$91M
Taavet Hinrikus
Angel
3 United Kingdom, United States, Estonia Seed, Series A, Series B FinTech, Financial Services, Software $910k–$50M
Global Asset Fund
VC Fund
3 Germany Series A, Series B Medical, Therapeutics, Biotechnology $1M–$2.8M
Lima Ventures
VC Fund
3 Turkey, Estonia, Germany Seed, Pre-Seed Artificial Intelligence, Software, FinTech $21k–$400k
BlueYard Capital
VC Fund
3 United States, Germany, France Seed, Series A Software, Cryptocurrency, Internet $1.1M–$42M
Delivery Hero Ventures
VC Fund
3 Singapore, Egypt, Brazil Series A, Seed, Series B E-Commerce, Information Technology, Food Delivery $5M–$17M
Andera Partners
VC Fund
3 France, United States, Germany Series B, Private Equity Biotechnology, Health Care, Medical $11M–$241M
IBB Ventures
VC Fund
3 Germany, United States, United Kingdom Seed, Series A Software, Health Care, Internet $820k–$7M
EQT Ventures
VC Fund
3 Sweden, Germany, United States Series A, Series B, Seed Software, Information Technology, SaaS $2M–$52M
LSP BioVentures
VC Fund
3 United States, Germany, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $5.3M–$83M
Seventure Partners
VC Fund
3 France, United States, Germany Series A, Series B Biotechnology, Health Care, Software $2.4M–$35M
Cascara Ventures
VC Fund
3 Germany, Finland, The Netherlands Series A, Seed, Series B Medical, Health Care, Biotechnology
German Federal Ministry of Education and Research (BMBF)
VC Fund
3 Germany, United States, Denmark Grant, Seed, Series B Biotechnology, Medical, Health Care $321k–$47M
VC Fonds Technologie Berlin
VC Fund
2 Germany, United States Seed, Series A, Series C Software, Health Care, Biotechnology
DvH Ventures
VC Fund
2 Germany, Austria, Liechtenstein Seed, Series A Financial Services, FinTech, Software $1M–$11M
ERP Startfonds
VC Fund
2 Germany, United States Series B, Series A Biotechnology, Pharmaceutical, Apps
Possible Ventures
VC Fund
2 Germany, Australia, United States Seed, Pre-Seed, Series A Software, Information Technology, Financial Services $350k–$43M
HBM Healthcare Investments AG
VC Fund
2 United States, Switzerland, China Series B, Series C, Series A Biotechnology, Health Care, Medical $3M–$200M
Thor Bjorgolfsson
Angel
2 United Kingdom, Germany Seed, Series A, Series C Big Data, TV, TV Production
Access all 538 investors in Germany Biotechnology startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

High-Tech Grunderfonds
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 34 investments in Germany Biotechnology startups, 64 in the past 12 months

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit, and passion, its teamof experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry, and life sciences.To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

Show more...

Investment focus

  • Industry: Software, Information Technology, Biotechnology
  • Stage:Seed, Series A
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 373
  • Round size: Seed $665k–$5.1M; Series A $1.5M–$16M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Inovedis — Inovedis offers innovative solutions in medical technology that contribute both to optimized patient care as well as time and cost reductions in the healthcare sector.
  • Resourcify — Mein Recycling is developed by Resourcify GmbH from Hamburg. The app is the easiest solution for businesses to easily manage all of their waste, collections, and recyclers in one app, and for waste management companies to seamlessly connect with their customers online. Their vision is zero-waste: enabled with the digital transformation of the wastesector as the foundation for the circular economy.
  • traceless materials — traceless materials offer a holistically sustainable alternative to plastics: 100% biobased on plant residues, compostable under natural conditions, and free of toxic chemicals. For a future free of pollution and waste!
Show all investments...

Boehringer Ingelheim Venture Fund
VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 16 investments in Germany Biotechnology startups

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Germany, Belgium

Investor stats

  • Total investments: 82
  • Round size: Seed $1.3M–$14M; Series A $3.8M–$29M; Series B $11M–$50M
  • Lead/follow: 49% lead, 51% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
  • smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
  • Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
Show all investments...

KfW
VC Fund · Frankfurt, Hessen, Germany · 15 investments in Germany Biotechnology startups

KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the Länder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Series A, Series B
  • Geography: Germany, India, Kenya

Investor stats

  • Total investments: 137
  • Round size: Series A $1.6M–$10M; Series B $3.2M–$17M
  • Lead/follow: 12% lead, 88% follow

Portfolio highlights

  • Uniper — Uniper is an international energy company with about 11,000 employees. They combine a balanced portfolio of technologically advanced large-scale assets with outstanding technical and commercial expertise. Uniper is a German energy company based in Dusseldorf, North Rhine-Westphalia. It was formed by the separation of E.ON's fossil fuel assetsinto a separate company that began operating on 1 January 2016.
  • NamPower — NamPower is the national power utility of Namibia and specializes in the generation and transmission of electricity.
  • Electrochaea — Electrochaea is commercializing a disruptive, scalable technology to convert electric power into methane, the principal component of natural gas. Using CO2 as a feedstock gas, power can be efficiently converted to renewable natural gas for power storage, for transportation fuels, or for transmission via a natural gas network. The company licensedtechnology from the University of Chicago and is led by the Nidus Partners, a St. Louis investment group specializing in renewable energy. Mich Hein, a Nidus Managing Partner, serves as CEO.Electrochaea has developed a commercially viable and disruptive solution for utility-scale energy storage, grid balancing, and carbon reuse. Their proprietary process converts low-cost and stranded electricity and carbon dioxide into pipeline-grade renewable gas for direct injection into the existing natural gas grid, a conversion process known as “power-to-gas”.
Show all investments...

NRW.BANK
VC Fund · Düsseldorf, Nordrhein-Westfalen, Germany · 15 investments in Germany Biotechnology startups

NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Seed, Series A, Series B
  • Geography: Germany, United States

Investor stats

  • Total investments: 79
  • Round size: Seed $107k–$7.5M; Series A $2.1M–$13M; Series B $2.7M–$9M
  • Lead/follow: 18% lead, 82% follow
  • Last fund: May invest from a new fund soon — raised $86M in 2011

Portfolio highlights

  • bNear — bNear is the digital space for all distributed- & hybrid teams - Safe and convenient in Microsoft Teams!
  • Companyon Analytics — Companyon Analytics provides data security, cloud infrastructure, information technology, technical solutions, and consultancy services.
  • Refined Laser Systems — Refined Laser Systems is a dynamic biophotonics company.It specialises in creating innovative laser systems for SRS-microscopy and quantum technology.
Show all investments...

MIG Capital
VC Fund · München, Bayern, Germany · 15 investments in Germany Biotechnology startups

Zusammen gestalten wir die Unternehmen von morgen.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series A, Series B
  • Geography: Germany, Austria, Canada

Investor stats

  • Total investments: 80
  • Round size: Series A $1.8M–$9M; Series B $1.6M–$26M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: May invest from a new fund soon — last raise in 2014

Portfolio highlights

  • AMSilk — AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.
  • mbiomics — mbiomics is a biotechnology company.
  • Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
Show all investments...

Bayern Kapital
VC Fund · Landshut, Bayern, Germany · 9 investments in Germany Biotechnology startups, 25 in the past 12 months

Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: Germany, United States, Finland

Investor stats

  • Total investments: 156
  • Round size: Seed $750k–$4.6M; Series A $1.5M–$16M
  • Lead/follow: 14% lead, 86% follow
  • Last fund: May invest from a new fund soon — last raise in 2010

Portfolio highlights

  • memtime — memtime shows you everything you worked on during the day. Each program is recorded so that you can quickly remember. Add-on available for any software. | memtime
  • FERNRIDE — Fernride enables automated, sustainable logistics by combining the skills of remote drivers with autonomous technologies.
  • Driveblocks — driveblocks' Mapless Autonomy Platform enables heavy duty vehicles to reliably detect objects and perceive their sourrounding without relying on high-definition maps. It's applications are container terminals, mining, agriculture, and hub-to-hub logistics. The technology unlocks cost-saving potentials, safety improvements and more efficient workflows.
Show all investments...

TGFS - Technologiegründerfonds Sachsen
VC Fund · Leipzig, Sachsen, Germany · 8 investments in Germany Biotechnology startups, 10 in the past 12 months

TGFS - Technologiegruenderfonds Sachsen is an early stage VC fund targeting high tech startups with strong growth potential. The fund invests into ventures located in Saxony/Germany, Europe's leading semiconductor cluster. The team has invested into more than 120 companies so far, including more than 40 investments from the currentfund.

Show more...

Investment focus

  • Industry: Software, Information Technology, Manufacturing
  • Stage:Seed, Series A
  • Geography: Germany, United States

Investor stats

  • Total investments: 116
  • Round size: Seed $563k–$3.5M; Series A $1.1M–$4.3M
  • Lead/follow: 21% lead, 79% follow
  • Last fund: May invest from a new fund soon — raised $69M in 2016

Portfolio highlights

  • MiViA — From microstructure segmentation to grain size measurement! Our AI engine provides a fast and reliable metallographic analysis for metallic products.}
  • BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
  • BirdsView — BirdsView is to 'assist small e-commerce firms in transforming their own consumer data into effective, tailored marketing tactics and turning one-time purchases into devoted patrons.
Show all investments...

Wellington Partners
VC Fund · Munich, Bayern, Germany · 8 investments in Germany Biotechnology startups

Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B
  • Geography: Germany, United States, United Kingdom

Investor stats

  • Total investments: 172
  • Round size: Series A $3M–$28M; Series B $6.7M–$43M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Nosto — Use Powerful Personalization Made Easy on e-Commerce Platforms. Nosto generates a 10-30% Average Increase in Revenue.
  • Minervax — MinervaX is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein : click to read more
  • Seamless Therapeutics — Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Seamless technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes.
Show all investments...

IFB Innovationsstarter
VC Fund · Hamburg, Hamburg, Germany · 7 investments in Germany Biotechnology startups

The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.

Show more...

Investment focus

  • Industry: Software, SaaS, Artificial Intelligence
  • Stage:Seed, Grant
  • Geography: Germany, United States

Investor stats

  • Total investments: 70
  • Round size: Seed $643k–$3M; Grant $80k–$161k
  • Lead/follow: 41% lead, 59% follow

Portfolio highlights

  • 3D Spark — Profitability and Sustainability Aligned using 3D Spark's Platform - Empowering Manufacturing with Insights and Efficiency!
  • Stargazr — Stargazr is a AI-powered software that enables you to understand your financial data
  • Neuralfinity — Neuralfinity provides computer AI services. They generalise machine learning models by utilising an ML API as a service.
Show all investments...

eCAPITAL ENTREPRENEURIAL PARTNERS
VC Fund · Münster, Nordrhein-Westfalen, Germany · 6 investments in Germany Biotechnology startups

eCAPITAL is a venture capital investor that provides early to growth stage funding to technology and deep tech companies.

Show more...

Investment focus

  • Industry: Information Technology, Software, Manufacturing
  • Stage:Series A, Series B
  • Geography: Germany, United States, Italy

Investor stats

  • Total investments: 101
  • Round size: Series A $2.7M–$4.9M; Series B $1.1M–$16M
  • Lead/follow: 76% lead, 24% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
  • Build38 — Build38 is a global provider of mobile application protection solutions. Its solution represents a new generation of app-hardening technologies and service that protects apps from known and unknown attacks and opens the market to new digital business models. Build38 protects applications across various industries including automotive, financial,public transport and health care. Build38 is headquartered in Munich with global offices in Barcelona and Singapore. The company is a spin out of Giesecke + Devrient and ranks among the best IT Security startups in Germany. Build38 is an official GARTNER In-App Shielding Market Guide Vendor since 2019 and the first to combine: In-App Shielding + In-App Monitoring + AI-based In-App Reaction.
  • QuoIntelligence — Our finished intelligence will significantly reduce your operational risks and allow you to make informed security decisions.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
coparion
VC Fund · Cologne, Nordrhein-Westfalen, Germany · 6 investments in Germany Biotechnology startups, 6 in the past 12 months

Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.

Show more...

Investment focus

  • Industry: Software, SaaS, FinTech
  • Stage:Series A, Seed, Series B
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 90
  • Round size: Seed $2M–$8.9M; Series A $4.5M–$14M; Series B $9.6M–$54M
  • Lead/follow: 3% lead, 97% follow
  • Last fund: May invest from a new fund soon — last raise in 2016

Portfolio highlights

  • Finoa — Finoa is the leading European crypto-asset management platform, empowering businesses and institutions to engage with crypto safely and intuitively.
  • ContractHero — ContractHero is a leading digital contract management solution for business customers. The smart and easy-to-use software provides an overview of all current contracts, quickly identifies unnecessary costs and reduces risks from missed contract deadlines. As a result, companies have full control over their contracts and avoid missed deadlines andunnecessary costs.
  • Finanzguru — Finanzguru is an AI based financial assistant.
Show all investments...

BioMedPartners
VC Fund · Basel, Basel-Stadt, Switzerland · 6 investments in Germany Biotechnology startups

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: Switzerland, Germany, France

Investor stats

  • Total investments: 80
  • Round size: Series A $5.4M–$20M; Series B $4.4M–$69M; Series C $5.2M–$21M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
  • ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
  • Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Show all investments...

bmp Ventures
VC Fund · Berlin, Berlin, Germany · 5 investments in Germany Biotechnology startups

bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.

Show more...

Investment focus

  • Industry: Information Technology, Software, Manufacturing
  • Stage:Seed, Series A
  • Geography: Germany, United States, Austria

Investor stats

  • Total investments: 102
  • Round size: Seed $148k–$2.4M; Series A $29k–$4.3M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: Likely still investing — raised $2.5M in 2022

Portfolio highlights

  • Neotiv — Enabling cognitive health
  • Wingfield — Wingfield ist dein Zugang zu einem virtuellen Tenniserlebnis.
  • InLine-Med — Radiologists perform safe, precise & easy interventions with the InLine-Med surgical tools and assistance devices.
Show all investments...

EMBL Ventures
VC Fund · Heidelberg, Baden-Wurttemberg, Germany · 5 investments in Germany Biotechnology startups

EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: Germany, Austria, Ireland

Investor stats

  • Total investments: 11
  • Round size: Series A $3.9M–$15M; Series B $19M–$70M
  • Lead/follow: 27% lead, 73% follow

Portfolio highlights

  • Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
  • Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
  • Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Show all investments...

Forbion Capital Partners
VC Fund · Naarden, Noord-Holland, The Netherlands · 5 investments in Germany Biotechnology startups, 8 in the past 12 months

Impacting the future of medicine.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, The Netherlands

Investor stats

  • Total investments: 118
  • Round size: Series A $4.5M–$30M; Series B $12M–$115M; Series C $5.6M–$65M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Mariana Oncology — Mariana Oncology is a biotechnology research industry.
  • Seamless Therapeutics — Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Seamless technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes.
  • Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is
Show all investments...

Techno Venture Management
VC Fund · Boston, Massachusetts, United States · 5 investments in Germany Biotechnology startups

Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, Germany, United Kingdom

Investor stats

  • Total investments: 61
  • Round size: Series A $4.7M–$15M; Series B $5.2M–$43M; Series C $4M–$22M
  • Lead/follow: 31% lead, 69% follow

Portfolio highlights

  • Streaming21 — Checkout the full domain details of Streaming21.com. Click Buy Now to instantly start the transaction or Make an offer to the seller!
  • Revolt Technology — News & Informations
  • Helomics — Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
Show all investments...

Creathor Ventures
VC Fund · Bad Homburg, Hessen, Germany · 5 investments in Germany Biotechnology startups

We have been investing at the frontier of technology and science for over 30 years. We know what it takes to succeed.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Series A, Series B
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 92
  • Round size: Series A $2M–$12M; Series B $5.1M–$16M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: May invest from a new fund soon — last raise in 2016

Portfolio highlights

  • Ledgy — Digitize your cap table, automate equity plans and simplify compliance. Find out how leading companies use Ledgy to empower their employees and engage investors.
  • HeyJobs — Intelligent recruiting | more hires with performance marketing | only qualified candidates | fast recruiting success | over 1,500 companies use HeyJobs to find employees
  • Humanoo — HUMANOO | MAKING PEOPLE HEALTHIER! HUMANOO is the digital health platform for employees and insurance clients. We enable our users to improve their physical and mental health. Simple, effective, proven - all in one app. With customized programs and innovative eHealth solutions, we guide our users in the areas of fitness, physio, yoga, mindfulnessand nutrition to their self-imposed goals. For the first time, companies and insurance companies can use comprehensive decentralized analysis to understand the health of their employees or insurance clients and make it a measurable success. Our team currently consists of 65 employees from 15 nations with different talents. In our office in Berlin-Kreuzberg, software developers, designers, marketing and sales specialists work together with sports and nutrition scientists as well as yoga teachers and physiotherapists. What we share is the goal to motivate people to stay healthy.
Show all investments...

bm-t beteiligungsmanagement thuringen
VC Fund · Erfurt, Thuringen, Germany · 5 investments in Germany Biotechnology startups

bm-t beteiligungsmanagement thüringen is a regional venture capital and private equity company with fokus on investments in the State of Thüringen in Germany only. We invest in innovative companies with strong growth potential across all sectors and all phases of the corporate lifecycle.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: Germany, United States

Investor stats

  • Total investments: 53
  • Round size: Seed $450k–$7M; Series A $1.1M–$2.9M
  • Lead/follow: 70% lead, 30% follow

Portfolio highlights

  • rooom.com — rooom is a global startup based in Germany, launched in 2019. The company’s experienceCloud is an all-in-one platform for creating, managing and promoting engaging 2D, 3D, AR & VR experiences. It works across all desktop and mobile devices. rooom’s experienceCloud is designed to cover the marketing and visualization needs of differentindustries through their comprehensive product portfolio. These include eventCloud (optimized for virtual events, exhibitions, conferences, meetings), spaceCloud (real estate, property, museums), productCloud (3D products, product showrooms) and immerseCloud (tours, guides, 3D books). rooom’s eventCloud is routinely hosting up to 200,000 users for hybrid events like IFA, Berlin and for global customers such as Porsche, Deutsche Telekom, DHL and E.ON. rooom has won over 20 awards, including the Global Eventex Award (twice), the Innovation & Excellence Award and the German Innovation Award.
  • tediro — tediro develops a mobile robotics platform for multiple applications in healthcare primarily therapy and diagnostics
  • Coachwhisperer — Coachwhisperer offers smart intercom and monitoring system for coaches and athletes.
Show all investments...

Brandenburg Kapital
VC Fund · Potsdam, Brandenburg, Germany · 4 investments in Germany Biotechnology startups, 8 in the past 12 months

With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: Germany, United Kingdom

Investor stats

  • Total investments: 53
  • Round size: Seed $696k–$2.1M; Series A $2.7M–$7.4M
  • Lead/follow: 45% lead, 55% follow

Portfolio highlights

  • Doctorflix — Doctorflix is a medical education platform that allows doctors around the globe to learn about methods of treatment while accelerating their system-required professional development. We are on a mission to build an engine that simplifies and democratizes the consumption and exchange of medical knowledge by interlinking doctors, hospitals, andpharmaceutical companies.
  • mama health — mama health is a platform to find others around the world living the same journey as you - and learn form each other's experience.
  • DearEmployee — DearEmployee is the Workplace Mental Health Platform. As a corporate health start-up, we support employers in designing healthy and motivating working conditions for their employees in order to reduce mental stress and to increase employee productivity. Using the DearEmployee platform, companies can easily and digitally measure mental stress at theworkplace in a scientific way, and subsequently sign up to tailored health and HR measures. The solution also meets the legal requirements for mental health risk assessment in Germany.
Show all investments...

Amino Collective
VC Fund · Berlin, Berlin, Germany · 4 investments in Germany Biotechnology startups

Amino Collective is an investment firm. They enable entrepreneurs and scientists to establish businesses that generate a better future for all species on Earth. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, life science, and synthetic biology.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Software
  • Stage:Seed, Series A, Pre-Seed
  • Geography: Germany, United States, United Kingdom

Investor stats

  • Total investments: 24
  • Round size: Seed $2.9M–$6M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Lindus Health — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
  • Enveda Biosciences — Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California.
  • Sensible Biotechnologies — Engineering cells to make better mRNA.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Seed Fonds Aachen
VC Fund · Aachen, Nordrhein-Westfalen, Germany · 4 investments in Germany Biotechnology startups

Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Seed, Series A
  • Geography: Germany

Investor stats

  • Total investments: 8
  • Round size: Series A $2.1M–$6M
  • Lead/follow: 25% lead, 75% follow

Portfolio highlights

  • miacosa — miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories.
  • Hemovent — ​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.
  • aquila biolabs — aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development.
Show all investments...

BayBG Venture Capital
VC Fund · München, Bayern, Germany · 4 investments in Germany Biotechnology startups, 8 in the past 12 months

Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Series A, Series B
  • Geography: Germany, Italy, United States

Investor stats

  • Total investments: 106
  • Round size: Series A $428k–$5.9M
  • Lead/follow: 27% lead, 73% follow

Portfolio highlights

  • memtime — memtime shows you everything you worked on during the day. Each program is recorded so that you can quickly remember. Add-on available for any software. | memtime
  • ChargeOne — The complete charging solution for your e-mobility.
  • SUSHI Bikes — SUSHI Bikes has developed the perfect e-bike for modern urban people.
Show all investments...

S-Venture Capital Dortmund
VC Fund · Deutsch, Sachsen, Germany · 4 investments in Germany Biotechnology startups

S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.

Show more...

Investment focus

  • Industry: Biotechnology, Guides, Genetics
  • Stage:Series B, Series A
  • Geography: Germany

Investor stats

  • Total investments: 9
  • Round size: Series B $3.5M–$9M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Innolume — Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power.
  • Protagen — Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
  • Scienion — SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields – from early research to manufacturing.
Show all investments...

EIC Fund
VC Fund · 3 investments in Germany Biotechnology startups, 21 in the past 12 months

start-ups, SMEs, technology, co-investment

Show more...

Investment focus

  • Stage:Seed
  • Geography: Germany

Investor stats

  • Total investments: 22
  • Lead/follow: no public data

Portfolio highlights

  • Filuta AI — Operationalized Composite Artificial Intelligence
  • Resistell AG — Resistell is a antibiotic resistance test.
  • iThera Medical — Due to its spatiotemporal resolution, penetration depth, sensitivity and specificity, optoacoustic imaging (OAI) can be used for a multitude of applications.
Show all investments...

TVM Capital
VC Fund · Munich, Bayern, Germany · 3 investments in Germany Biotechnology startups

TVM Capital Group is an affiliation of globally acting venture capital and private equity firms with an operating track record of more than 30 years.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series B, Series C
  • Geography: United States, Germany, United Kingdom

Investor stats

  • Total investments: 101
  • Round size: Series B $7.5M–$49M; Series C $10M–$54M
  • Lead/follow: 19% lead, 81% follow
  • Last fund: May invest from a new fund soon — last raise in 2005

Portfolio highlights

  • Definiens — Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
  • Lamab Biologics — Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases.
  • Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Show all investments...

CPT Capital
VC Fund · London, England, United Kingdom · 3 investments in Germany Biotechnology startups

Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.

Show more...

Investment focus

  • Industry: Food and Beverage, Food Processing, Biotechnology
  • Stage:Series A, Seed, Series B
  • Geography: United States, Israel, United Kingdom

Investor stats

  • Total investments: 47
  • Round size: Seed $1.2M–$20M; Series A $2.5M–$20M; Series B $15M–$226M
  • Lead/follow: 12% lead, 88% follow

Portfolio highlights

  • PoLoPo — PoLoPo is a biotech company that produces proteins on a large scale and according to specifications. PoLoPo develops a "superAA" plant by employing directed metabolic engineering techniques and fully utilizing plants' capacity as various metabolite and green protein factories. A significant amount of free amino acids can be producedby the superAA. The increased production of amino acids is then translated into an increase in the scale at which proteins are produced in plant organs.
  • Equinom — Equinom is a fully integrated food-tech company, combining agricultural know-how, culinary expertise and deep technology to develop delicious, nutritious, affordable and sustainable non-GMO plant-based ingredients – from the ground up.Sustainable, plant-based proteins are key to feeding Earth’s 10B people by 2050 The plant-based food market grew27% in 2020 and is projected to reach $162B by 2030.The industry is unable to supply the full demand for food vs. feed For decades, crops have been farmed primarily for animal feed – not for human consumption. To be palatable in human food, these crops require extensive and expensive processing. . With limited processing facilities equipped for this use, the industry is on track to supply only 50% of projected demand for plant-based foods.What is Equinom doing about it? Equinom is using science and technology to develop superior ingredients naturally, at the source – in a fraction of the time typically required to breed new crops. Equinom crops are bred naturally, without genetic editing or modification, and are optimized to make meat and dairy analogues more delicious, nutritious, cost-effective and sustainable. Ingredients designed by deep tech to bring out nature’s best The company’s proprietary Manna™ technology platform uses AI to speed the development of superior, high-yield, non-GMO ingredients as nature intended – featuring the quality traits that satisfy consumer expectations. The technology also ensures biodiversity and climate resilience that are critical to ensure food security in light of climate change. What makes Equinom a compelling foodtech investment and collaborator? Working with great partners including Meatless Farm, Roquette with GoodMills Group., Equinom is recognized as a trusted developer and supplier of unrivaled ingredients. Prestigious strategic investors such as BASF and Roquette have helped position Equinom as one of the breakout Round C companies to fuel the worldwide surge in plant-based eating.
  • Liberation Labs — Liberation Labs believe that by innovating technology, It can free the world from the costs of industrialized agriculture and unlock a new era of accessible, healthy foods. The mission is to make precision fermentation by commercializing purpose-built manufacturing facilities for industrial biotech.
Show all investments...

Grazia Equity
VC Fund · Stuttgart, Baden-Wurttemberg, Germany · 3 investments in Germany Biotechnology startups

Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.

Show more...

Investment focus

  • Industry: Internet, E-Commerce, Biotechnology
  • Stage:Series A, Seed, Series B
  • Geography: Germany, United States, Switzerland

Investor stats

  • Total investments: 72
  • Round size: Seed $964k–$11M; Series A $1.1M–$12M; Series B $2.4M–$15M
  • Lead/follow: 36% lead, 64% follow

Portfolio highlights

  • VYTAL — Start the Packaging Revolution! We are offering smart & reusable To-Go Packaging-as-a-Service to gastronomy clients & consumers.In Germany the consumption of take-away, convenience and delivery food & drinks is responsible for about 281 kilotons of single-use packaging waste for immediate consumption and is growing at double digitrates. Most of the time, To-Go food containers, snack boxes or coffee cups have a very short life-span of only 30 minutes after which they are tossed into trash (or litter parks, beaches & the ocean). This is not only a giant waste of economic resources as each single use costs between 15 and up to 0,60€ for a stable bowl/box with a lid. It is a horrendous waste of environmental resources (wood, water, crude oil, metals & energy) that are used to produce this packaging. Therefore, a single use packaging not weighing more than 30 grams can easily come with an ecological backpack of more than 8 kilograms when taking into account all the resources used in production (material intensities taken from Wuppertal Institute for Climate, Environment and Energy). Looking at GHG emissions, the picture is similarly bleak: Using CO2 emission factors and the detailed material mix of the single-use packaging waste analyzed by NABU (German Nature and Biodiversity Conservation Union), the 281 thousand tons waste from To-Go consumption generated around 556 thousand tons of CO2 or the equivalent of 195k passenger cars per year (assuming an average distance travelled of 15,000km). With the expected rise of take-away, convenience and delivery food, the related emissions are expected to increase at double digit rates as waste volume is expected to increase and as we saw a shift to plastics relative to cardboard or other materials. While there is a growing awareness of the problem, especially in Germany, there is no scalable solution yet and the commonly used alternative of nature-based & ‘biodegradable’ materials like bagasse or PLA also require many resources for production & transport, and have to be incinerated or go to landfill after use as there is currently no way to compost them.
  • ZAGENO — ZAGENO is a multi-vendor, online marketplace of life science products which, by simplifying the procurement process, saves more time for science.
  • Hypatos — Manual document processing is a major cost driver. Hypatos' deep learning tech automates complex document processing tasks. Make back office more efficient!
Show all investments...

OCCIDENT
VC Fund · Zug, Zug, Switzerland · 3 investments in Germany Biotechnology startups, 6 in the past 12 months

Occident macht Investments in Deep Tech Startups aus den Bereichen Lifesciences, Hightech und Digital. Finanzierung ab Seed-Finanzierungsrunde

Show more...

Investment focus

  • Industry: Health Care, Medical Device, Biotechnology
  • Stage:Series A, Series C
  • Geography: Germany, Switzerland

Investor stats

  • Total investments: 23
  • Round size: Series A $2.1M–$6.7M; Series C $7.6M–$24M
  • Lead/follow: 35% lead, 65% follow

Portfolio highlights

  • ReCatalyst — REvolutionizing the way we make fuel cell CATALYSTs
  • iThera Medical — Due to its spatiotemporal resolution, penetration depth, sensitivity and specificity, optoacoustic imaging (OAI) can be used for a multitude of applications.
  • Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research
Show all investments...

Gilde Healthcare
VC Fund · Utrecht, Utrecht, The Netherlands · 3 investments in Germany Biotechnology startups, 6 in the past 12 months

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series C, Series B, Series A
  • Geography: United States, The Netherlands, Germany

Investor stats

  • Total investments: 100
  • Round size: Series A $8.6M–$47M; Series B $8M–$60M; Series C $21M–$50M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • GT Medical Technologies — At GT Medical Technologies, our purpose is Improving the Lives of Patients with Brain Tumors. GammaTile Therapy is Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors.
Show all investments...

EQT life science
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 3 investments in Germany Biotechnology startups, 6 in the past 12 months

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, The Netherlands, Switzerland

Investor stats

  • Total investments: 132
  • Round size: Series A $6.4M–$50M; Series B $5.4M–$69M; Series C $10M–$70M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: Likely still investing — raised $279M in 2023

Portfolio highlights

  • VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
  • Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
  • Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Think.Health
VC Fund · Fürstenfeldbruck, Bayern, Germany · 3 investments in Germany Biotechnology startups

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Seed, Series A, Series B
  • Geography: Germany, United States, Switzerland

Investor stats

  • Total investments: 31
  • Round size: Seed $1.1M–$8.3M; Series A $3.5M–$19M
  • Lead/follow: 32% lead, 68% follow

Portfolio highlights

  • Vara — Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with.
  • anvajo — Originally started at TU Dresden, anvajo can now look back on several years of innovative research and successful product development with uninterrupted growth. As part of the business expansion and ongoing team building, anvajo moved into its new headquarters in Dresden in January 2020. On 1300 m² practically all areas, including development,production and support functions are united under one roof.
  • Navignostics — Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient.
Show all investments...

UVC Partners
VC Fund · Munich, Bayern, Germany · 3 investments in Germany Biotechnology startups, 8 in the past 12 months

UVC Partners is a Munich- and Berlin-based early-stage venture capital firm that invests in technology-based startups in the areas of enterprise software, industrial technologies, and mobility. The fund typically invests between € 0.5 - 10m initially and up to € 20m in total per company.

Show more...

Investment focus

  • Industry: Software, Information Technology, Artificial Intelligence
  • Stage:Seed, Series A, Series B
  • Geography: Germany, Switzerland, Denmark

Investor stats

  • Total investments: 95
  • Round size: Seed $2.5M–$11M; Series A $4.7M–$25M; Series B $2.5M–$91M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • Stabl Energy — Stabl Energy is a developer of a technology that significantly improves battery storage systems.
  • Proxima Fusion — We are a European fusion energy startup pursuing the clearest path to grid deployment.
  • ChargeX — ChargeX provides electric car charging solutions. Tobias Wagner, Michael Masnitza, and Johannes Engeln founded it in 2017, with its headquarters in Munich in Germany.
Show all investments...

Taavet Hinrikus
Angel · London, England, United Kingdom · 3 investments in Germany Biotechnology startups

Taavet Hinrikus is co-founder and CEO of TransferWise. Prior to starting TransferWise, Taavet was Skype’s director of strategy until 2008, starting as its first-ever employee. One of the World Economic Forum's Tech Pioneers, Taavet is an adviser to Prime Minister of Estonia on the digital agenda. He’s also a mentor and angel investor; hisinvestments include Tweetdeck, Mendeley, OMGPOP, Property Partner, Sunrise, Improbable and Mapillary.

Show more...

Investment focus

  • Industry: FinTech, Financial Services, Software
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Estonia

Investor stats

  • Total investments: 109
  • Round size: Seed $910k–$7.5M; Series A $5M–$31M; Series B $50M–$50M
  • Lead/follow: 11% lead, 89% follow

Portfolio highlights

  • Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
  • Open Cosmos — Driven by the vision of making space accessible to anyone, Open Cosmos provides simple and affordable space missions.Open Cosmos went from design to delivery of qb01, their first nanosatellite, in only four months, followed by a launch and deployment in LEO early April 2017. They are currently working with innovative payload developers towardsin-orbit demonstration and constellation deployment to enable services ranging from remote sensing to maritime domain awareness and machine-to-machine communications.
  • Unearthly Materials — Unearthly Materials is a transformative materials company focused on delivering practical room-temperature superconductors and powering the century of superconductivity.
Show all investments...

Global Asset Fund
VC Fund · Landshut, Bayern, Germany · 3 investments in Germany Biotechnology startups

Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.

Show more...

Investment focus

  • Industry: Medical, Therapeutics, Biotechnology
  • Stage:Series A, Series B
  • Geography: Germany

Investor stats

  • Total investments: 8
  • Round size: Series A $1M–$1.8M; Series B $1.6M–$2.8M
  • Lead/follow: 13% lead, 87% follow

Portfolio highlights

  • Siltectra — SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.
  • Isarna Therapeutics — Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
Show all investments...

Lima Ventures
VC Fund · Istanbul, Istanbul, Turkey · 3 investments in Germany Biotechnology startups, 7 in the past 12 months

Collaboration with outstanding initiators with exceptional insights, from inception through all levels of progress. Lima Ventures supports visionary founders as well as provides certain services to early startups. We seek innovative technology-driven entrepreneurs who generate and lead companies that will inspire millions.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Software, FinTech
  • Stage:Seed, Pre-Seed
  • Geography: Turkey, Estonia, Germany

Investor stats

  • Total investments: 28
  • Round size: Seed $21k–$400k
  • Lead/follow: 7% lead, 93% follow

Portfolio highlights

  • VRLab Academy — VRLab Academy specializes in implementing advanced virtual science education to institutions. It focuses on waste-free, attractive, and useful design to makes advanced virtual science education possible. The company aims to evolve the educational environment where students will improve their scientific skills and learn all about it from firsthand.
  • Studio Billion — Studio Billion is a game development company that develops applications, games, and projects for different platforms. Studio Billion is headquartered in Istanbul, Turkey.
  • Enqura Information Technologies — Enqura Information Technologies offers advanced technologies in conjunction with human resources as reasonable solutions. Enqura develops creative solutions in the field of digital transformation. They provide innovative and end-to-end solutions to several industries, primarily finance and insurance.
Show all investments...

BlueYard Capital
VC Fund · Berlin, Berlin, Germany · 3 investments in Germany Biotechnology startups, 14 in the past 12 months

BlueYard backs founders building the interconnected elements that can become the fabric of our future.

Show more...

Investment focus

  • Industry: Software, Cryptocurrency, Internet
  • Stage:Seed, Series A
  • Geography: United States, Germany, France

Investor stats

  • Total investments: 68
  • Round size: Seed $1.1M–$8.3M; Series A $9.5M–$42M
  • Lead/follow: 43% lead, 57% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Chemify — The aim of Chemify is to digitize chemistry and produce solutions to run chemical code for drug discovery, chemical synthesis, and materials discovery.
  • Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
  • Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
Show all investments...

Delivery Hero Ventures
VC Fund · Berlin, Berlin, Germany · 3 investments in Germany Biotechnology startups, 7 in the past 12 months

Delivery Hero Ventures is backed by Delivery Hero, a truly global food delivery platform - whose network, distribution and expertise can be harnessed to help our portfolio companies fulfill their global ambitions.

Show more...

Investment focus

  • Industry: E-Commerce, Information Technology, Food Delivery
  • Stage:Series A, Seed, Series B
  • Geography: Singapore, Egypt, Brazil

Investor stats

  • Total investments: 23
  • Round size: Series A $5M–$17M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — last raise in 2021

Portfolio highlights

  • Qashier — One Qashier solution streamlines POS & payment operations empowering businesses to thrive in the digital economy. Be More with Qashier.
  • Flash Coffee — Flash Coffee is a tech-enabled coffee chain that customers use their app to order and pay online, choosing to pick up orders from one of the Flash Coffee’s storefronts or order for delivery through major platforms in each market. Flash Coffee was founded in 2019 and is headquartered in Singapore.
  • Bluu Seafood — Cultivated Seafood Made From Fish Cells. Tastier, Healther and More Sustainable.
Show all investments...

Andera Partners
VC Fund · Paris, Ile-de-France, France · 3 investments in Germany Biotechnology startups, 9 in the past 12 months

Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Private Equity
  • Geography: France, United States, Germany

Investor stats

  • Total investments: 146
  • Round size: Series B $11M–$75M; Private Equity $107M–$241M
  • Lead/follow: 39% lead, 61% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
  • Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
  • Ariceum Therapeutics — Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Show all investments...

IBB Ventures
VC Fund · Berlin, Berlin, Germany · 3 investments in Germany Biotechnology startups, 10 in the past 12 months

IBB Ventures is a venture capital and mezzanine arm of Investitionsbank Berlin specializing in seed/startup, early venture, and mid venture investments. The firm invests in technology-oriented companies and companies from the creative industries. It typically invests in information and communication sector with a focus on hardware andsoftware, network technology, new media, and internet and mobile technologies; life science sector with a focus on biotechnology and media technology; and industrial technologies sector with a focus on software, PPS, supply chain management, micro and nanotechnology, environmental and power technology, automation, manufacturing technology, transport technology and logistics, and new materials. The firm also invests in movies, broadcast, television, publisher, music, entertainment, advertising, fashion, design, architecture, multimedia, games, software, and art and culture. It invests in companies based in Berlin. It typically invests between €0.25 million ($0.32 million) and €3 million ($3.83 million) per transaction. The firm prefers to take a board seat in its portfolio companies. IBB Ventures was founded in 1997 and is based in Berlin, Germany.

Show more...

Investment focus

  • Industry: Software, Health Care, Internet
  • Stage:Seed, Series A
  • Geography: Germany, United States, United Kingdom

Investor stats

  • Total investments: 169
  • Round size: Seed $820k–$4.3M; Series A $2.1M–$7M
  • Lead/follow: 16% lead, 84% follow
  • Last fund: Likely still investing — raised $32M in 2022

Portfolio highlights

  • nuwo — Workplace as-a-Service. nuwo is the #1 platform 
for financing, equipping 
and managing hybrid 
workspaces
  • MERSOR — MERSOR is an online marketplace for stylish and pre-curated gifts with a unique and innovative customer experience. We aim to make gifting easy, fast and fun again by not only providing the perfect gift but also assisting the customers in their overall gift management.
  • Wonnda — Wonnda is the digital infrastructure where buyers and suppliers collaboratively build the consumer products of tomorrow
Show all investments...

EQT Ventures
VC Fund · Stockholm, Stockholms Lan, Sweden · 3 investments in Germany Biotechnology startups, 20 in the past 12 months

EQT Ventures is a European VC fund with just over €2.3 billion in total capital raised. EQT Ventures I launched in May 2016, with commitments totalling €566 million and a simple mission - to be the kind of VC the team would have liked to have had on their own startup journeys. Recognizing that building and growing a company takes more than justcapital, the EQT Ventures team provides founders with support and advice throughout different stages of growth. EQT Ventures doesn't focus on particular markets or industries, but bold and ambitious founders who have the grit and determination to build global success stories. EQT Ventures II launched in November 2019, with commitments totalling €660 million. EQT Ventures III launched in 2022, with commitments totalling €1.1 billion, making it the biggest European Venture Capital fund committed to early stage tech startups. The EQT Ventures team is based across six offices in London, Stockholm, Berlin, Paris, Amsterdam, Paris and San Francisco, taking a locals with locals approach and supporting founders on the ground. Motherbrain, EQT Ventures' in-house-developed artificial intelligence (AI) platform, ensures the team has data-driven approach and has driven more than $100 million in portfolio company investments.

Show more...

Investment focus

  • Industry: Software, Information Technology, SaaS
  • Stage:Series A, Series B, Seed
  • Geography: Sweden, Germany, United States

Investor stats

  • Total investments: 162
  • Round size: Seed $2M–$11M; Series A $5.4M–$43M; Series B $14M–$52M
  • Lead/follow: 58% lead, 42% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Fly.io — Fly.io offers an Application Delivery Network (ADN) intended to help website owners get connected with their customers easily. The company's application delivery network uses a global network of servers to accept visitor traffic, run middleware on requests, then route them to backend applications, enabling website owners to direct theirvisitors to their respective sites securely and in a few clicks.
  • Verkor — Verkor is a French industrial company set to amplify battery cell production.
  • Volt.io — Increase retention and digital sales by allowing your customers to initiate direct payments, from their bank accounts to yours in real-time. Your checkout in super-drive, powered by Volt.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
LSP BioVentures
VC Fund · Cambridge, Massachusetts, United States · 3 investments in Germany Biotechnology startups

LSP BioVentures is a venture capital fund focused on opportunities in the life science arena. Based in Cambridge (MA) in the USA; the fund’s management combines the strength of its parent company, Life Sciences Partners Venture Capital firm in Europe and a dedicated team of experts in the USA.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Germany, United Kingdom

Investor stats

  • Total investments: 23
  • Round size: Series A $5.4M–$83M; Series B $5.3M–$35M; Series C $8M–$43M
  • Lead/follow: 52% lead, 48% follow
  • Last fund: Likely still investing — raised $1.1B in 2022

Portfolio highlights

  • Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
  • Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
  • HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.
Show all investments...

Seventure Partners
VC Fund · Paris, Ile-de-France, France · 3 investments in Germany Biotechnology startups, 7 in the past 12 months

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series A, Series B
  • Geography: France, United States, Germany

Investor stats

  • Total investments: 175
  • Round size: Series A $2.4M–$18M; Series B $3M–$35M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
  • Allozymes — Allozymes, Pte. Ltd. is a leading deep technology company applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. We developed sensitive, accurate, and generic assays for the detection of enzymatic reactions, proprietary microfluidic chips and proteomics technologies to take enzymedevelopment to the next level.
  • Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Show all investments...

Cascara Ventures
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 3 investments in Germany Biotechnology startups

96 Normal 0 false false false EN-GB X-NONE X-NONE

Show more...

Investment focus

  • Industry: Medical, Health Care, Biotechnology
  • Stage:Series A, Seed, Series B
  • Geography: Germany, Finland, The Netherlands

Investor stats

  • Total investments: 11
  • Lead/follow: 9% lead, 91% follow

Portfolio highlights

  • Surgify — Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa).
  • ATRO Medical — ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype.
  • microDimensions — microDimensions provides digital pathology software and services: image analysis, 3D histology reconstruction, protein multiplexing, stereology, image registration.
Show all investments...

German Federal Ministry of Education and Research (BMBF)
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 3 investments in Germany Biotechnology startups

German Federal Ministry of Education and Research (BMBF)

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Grant, Seed, Series B
  • Geography: Germany, United States, Denmark

Investor stats

  • Total investments: 38
  • Round size: Grant $321k–$47M
  • Lead/follow: 61% lead, 39% follow

Portfolio highlights

  • InflaRx — InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.In April 2018, InflaRx conducted a USD 117 million totalgross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany.
  • Evotec — Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances,development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased, and comprehensive infrastructure.Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases, and with Celgene in the field of neurodegenerative diseases.
  • NVision Imaging Technologies — NVision Imaging Technologies is leveraging advances in quantum physics to enable the first routine, convenient and affordable use of Magnetic Resonance Imaging (MRI) for assessing early patient response to cancer treatment at the metabolic level.
Show all investments...

VC Fonds Technologie Berlin
VC Fund · Berlin, Berlin, Germany · 2 investments in Germany Biotechnology startups

VC Fonds Technologie Berlin GmbH is a joint initiative of Investitionsbank Berlin (IBB) and the State of Berlin.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Series A, Series C
  • Geography: Germany, United States

Investor stats

  • Total investments: 13
  • Lead/follow: no public data

Portfolio highlights

  • Mika — Mika is a digital platform empowering people affected by cancer.
  • German Autolabs — German Autolabs builds powerful voice assistance tools to augment the daily workflows of professional drivers, couriers and delivery teams.
  • OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Show all investments...

DvH Ventures
VC Fund · Köln, Nordrhein-Westfalen, Germany · 2 investments in Germany Biotechnology startups, 9 in the past 12 months

Investing early in Europe's most passionate founders.

Show more...

Investment focus

  • Industry: Financial Services, FinTech, Software
  • Stage:Seed, Series A
  • Geography: Germany, Austria, Liechtenstein

Investor stats

  • Total investments: 61
  • Round size: Seed $1M–$7.5M; Series A $2.5M–$11M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: May invest from a new fund soon — last raise in 2017

Portfolio highlights

  • Dr. Vivien Karl — Dr. Vivien Karl relies on a cream for moisturizing care against vulva dryness.
  • Virtonomy GmbH — Virtonomy is shortening time-to-market of medical products by conducting data driven studies on virtual patients.
  • Broken String Biosciences — Our platform accelerates the characterisation of novel gene editing technologies to unlock the next wave of cell & gene therapies.
Show all investments...

ERP Startfonds
VC Fund · Frankfurt, Hessen, Germany · 2 investments in Germany Biotechnology startups

ERP Startfonds KfW finances and supports, among other things, business start-ups, small and medium-sized enterprises.

Show more...

Investment focus

  • Industry: Biotechnology, Pharmaceutical, Apps
  • Stage:Series B, Series A
  • Geography: Germany, United States

Investor stats

  • Total investments: 5
  • Lead/follow: no public data

Portfolio highlights

  • tolingo — tolingo is one of the most renowned and successful translation agencies in Germany – a fact which motivates us in our work across every division of our company every day and helps drive us to constantly improve the services we offer to our clients. A human touch is crucial, whether in terms of our employees’ respectful, open interaction with oneanother at our headquarters in Hamburg, our consultations and service meetings with our clients, or the close, productive working relationships we enjoy with our specialist translators and industry experts all over the world. We strive for collaborative success and partnerships on equal footing without losing sight of the expectations we’ve set for ourselves or the standards and goals we’re determined to meet. This is how we’ve been able to transform from a little translation agency into a globally present provider with a sophisticated portfolio of services – with market-leader status in our sights.
  • Rodos BioTarget — Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response - i.e., directly into antigen-presenting cells.RBT currently applies its TargoSphere® technology successfullyin various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.
  • Intelligent Apps — In 2009 founders Niclaus Mewes and Sven Kuelper launched "mytaxi" - the first taxi app with a direct connection between passenger and driver. mytaxi has grown to the fastest growing taxi-app with more than 7 million downloads and 35.000 connected taxis. mytaxi is available in over 40 German cities as well as Washington, Madrid, Barcelona,Warsaw, Vienna, Graz, Salzburg and Zurich. Investors include T-Venture Holding GmbH (Deutsche Telekom AG), Daimler Mobility Services GmbH (Daimler AG), KfW, e42 GmbH and Lars Hinrichs (Cinco Capital GmbH).mytaxi brings a demand for quality to the taxi service for the first time. Every driver using mytaxi has the ability to become a contractor and build their own client base by consistently providing passengers with good service and earning high customer ratings. Through the given peer-to-peer connection between passenger and driver the whole ordering process becomes very transparent for both. The passenger can not only track the taxi’s arrival in the app but also see which driver is coming. For the driver the cost modell is very attractive as they only pay for a successfully completed trip.The aim of mytaxi is to drive the concept of urban mobility and to further strengthen its position as an international leader in this field. Accordingly to that mytaxi took over the app development services for Daimler Mobility Services GmbH (Daimler AG).
Show all investments...

Possible Ventures
VC Fund · 2 investments in Germany Biotechnology startups, 20 in the past 12 months

Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.

Show more...

Investment focus

  • Industry: Software, Information Technology, Financial Services
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Germany, Australia, United States

Investor stats

  • Total investments: 100
  • Round size: Seed $2M–$7M; Pre-Seed $350k–$2.5M; Series A $6.9M–$43M
  • Lead/follow: 3% lead, 97% follow

Portfolio highlights

  • Farmless — A farmless fermentation platform has the potential to create an entirely new food repertoire, producing proteins, carbohydrates, beneficial fats, vitamins, and minerals from the ground up," explained Oner. "We are creating a new interface between food and electricity by domesticating microbes chosen for their food properties and abilityto grow on renewable energy-based feedstocks.
  • Spoke.ai — Spoke.ai uses powerful AI to help you cut through workplace noise, achieve inbox zero across all your tools, and summarize Slack conversations with ease.
  • Sumday — Non - financial accounting software. Start carbon accounting, properly, with the support of your existing advisors
Show all investments...

HBM Healthcare Investments AG
VC Fund · Zug, Zug, Switzerland · 2 investments in Germany Biotechnology startups

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The companyfocuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series C, Series A
  • Geography: United States, Switzerland, China

Investor stats

  • Total investments: 170
  • Round size: Series A $10M–$200M; Series B $9M–$165M; Series C $3M–$125M
  • Lead/follow: 19% lead, 81% follow

Portfolio highlights

  • ArriVent Biopharma — Leveraging Global Discoveries, Arrivent Biopharma is Building a Unique Handpicked Pipeline GroundedIn Innovative Science
  • FogPharma — FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together withworld-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.We are laser-focused and unstoppable in our mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.
  • Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
Show all investments...

Thor Bjorgolfsson
Angel · London, England, United Kingdom · 2 investments in Germany Biotechnology startups

Thor Bjorgolfsson - Entrepreneur, Businessman and Adventure Capitalist Thor Bjorgolfsson, Iceland’s first and only current billionaire, is an investor and business innovator who is not afraid of risk. He has been an entrepreneur since childhood, making his first deal at the age of 10, when he purchased a stack of vintage Marvel comics withborrowed money.In 2004, he founded Novator Partners, an alternative investment firm. He has strategically developed the company to allow it to maintain maximum flexibility as well as to facilitate investments in both strategic (buy and hold) and financial (buy and exit) opportunities.With Novator, Thor leverages private equity as well as macro investments and manages assets across a variety of sectors and geographic locations. He is an active investor in emerging economies including Central and Eastern Europe as well as Latin America.Novator Partners has been a major player in telecom businesses. Thor is a stakeholder in a Polish telecom company called Play, which went public in 2017. In addition, he holds shares in WOM, a Chilean telecommunications firm.Bjorgolfsson’s first fortune was made in post-soviet Russia. At a time when others perceived Russia to be tumultuous, he saw an underserved market that presented an exciting opportunity to invest in great ideas and businesses. He co-founded and developed Bravo Brewery, which produced beer and alcopops. Bravo became one of Russia’s premier brewing companies, particularly through its popular Botchkarov beer brand. Thor sold the business in 2002 to Heineken for $100 million.With the sale of Bravo, he was able to diversify his holdings by reinvesting in new ventures, focusing on telecommunications, pharmaceuticals, and banks. In a few years, he was able to turn that $100 million into a net worth of over $2.1 billion.A year after being featured on the 2007 cover of Forbes Magazine, Iceland went nearly bankrupt overnight and Thor found himself at the epicenter of the financial crisis. As a major shareholder in Landsbanki with personal guarantees of 350m euro, he refused to declare bankruptcy and eventually succeeded in paying off all of it. He then went on to invest in new businesses, re-establishing himself and being featured on the Forbes list of billionaires once again.During this time of rejuvenation, he wrote Billions to Bust and Back: How I Made, Lost and Rebuilt a Fortune, And What I Learned on the Way (2014). In the book, he shares his perspective of what it was like to be at the center of the storm and how he made it back to financial success. He proposes that the greatest strength an entrepreneur can possess is a positive attitude.The 52-year-old Thor was educated in the United States where he earned a Bachelor of Science degree from New York University. In 2005, he was honored as a Young Global Leader by the World Economic Forum. In spite of his intense schedule, Thor enjoys sharing his experience and business insight, making him a sought-after speaker. A multilingual Icelandic citizen, Thor spends most of his time in London, living with his wife and three children. Thor's personal passion is his collection of six motorcycles, which he rides whenever time permits.

Show more...

Investment focus

  • Industry: Big Data, TV, TV Production
  • Stage:Seed, Series A, Series C
  • Geography: United Kingdom, Germany

Investor stats

  • Total investments: 6
  • Lead/follow: 67% lead, 33% follow

Portfolio highlights

  • Olvin — Using foot traffic analytics to help your business make the right decisions. Get started to access world class data and actionable insights.
  • DNEG — We are DNEG, one of the world's leading visual effects and animation studios for feature film and television, honoured with the Academy Award six times
  • ATAI Life Sciences — ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in themental health space.ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.
Show all investments...

Biotechnology Investor funding in Germany at a glance

Stats across 486 deals from 538 investors.

538
investors
in Germany Biotechnology startups
486
deals
in Germany Biotechnology startups
$7.5M
median round
in Germany Biotechnology startups
37%
lead investors
lead at least one round
20%
Series A
most common funding stage
89/11
VC / Angel
share of investor count

Access all 538 investors in Germany Biotechnology startups.

Open List

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotechnology Investors in Germany investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 538 investors investing in Germany Biotechnology startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists